Table 4.
Preclinical studies of human NK therapy for lymphoma
| NK source | Activation and expansion method | Genetically engineered | Engineering method | Combination | Lymphoma subtype | Study stage | Year | Ref |
|---|---|---|---|---|---|---|---|---|
| NK-92 | IL-2 | No | N/A | Human BL | Preclinical | 1994 | [59] | |
| haNK | N/A | Yes (CD16-158V and erIL2) | Transfection/insertion | rituximab | Human CD20+ lymphoma | Preclinical | 2016 | [60] |
| CB | Anti-CD3, IL2, IL7, IL12 | No | No | N/A | Human BL | Preclinical | 2009 | [64] |
| hESC | NK differentiation medium (IL15, IL3, IL7, SCF, Flt3L) and irradiated AFT-24 cells | No | No | rituximab | Human BL | Preclinical | 2005 | [67] |
| iPSC | N/A | Yes (ADAM17 knockdown) | CRISPR/Cas9 | rituximab | Human BL | Preclinical | 2020 | [69] |
| PB | IL12, IL15, IL18 | No | No | rituximab | Human BL | Preclinical | 2017 | [88–90] |
| PB | NAM, IL2, IL15 | No | No | No | Human BL | Preclinical | 2011 | [79] |
| PB | irradiated autologous PBMCs | No | No | No | Human BL | Preclinical | 2013, 2013, 2017 | [71–73] |
| PB | irradiated k562-mbIL15-41BBL | No | No | No | Human BL | Preclinical | 2013 | [77] |
| CB | irradiated k562-mbIL15-41BBL | No | No | No | Human BL DLBCL | Preclinical | 2017 | [76] |
| PB | irradiated k562-mbIL21-41BBL | No | No | No | Human BL | Preclinical | 2012 | [78] |
| PB | irradiated k562-mbIL15-41BBL | Yes (anti-CD19 CAR) | mRNA electroporation | No | Human BL | Preclinical | 2012 | [83] |
| PB | irradiated k562-mbIL15-41BBL | Yes (anti-CD20 CAR) | mRNA electroporation | No | rituximab sensitive and resistant human BL | Preclinical | 2015 | [84] |
| PB | irradiated k562-mbIL15-41BBL | Yes (anti-CD20 CAR) | mRNA electroporation | romidepsin | rituximab sensitive and resistant human BL | Preclinical | 2017 | [85] |
| NK-92 | IL2 | Yes (anti-CD19 CAR) | Lentiviral transduction | No | Human BL, DLBCL | Preclinical | 2020 | [86] |
| CB | irradiated k562-mbIL21-41BBL | Yes (anti-CD19 CAR-IL15-iC9) | Retroviral transdduction | No | Human BL | Preclinical | 2019 | [56] |
| PB | IL12, IL15, IL18 | Yes (anti-CD19 CAR) | N/A | No | Human BL | Preclinical | 2020 | [91] |
| iPSC (FT596) | N/A | Yes (anti-CD19 CAR-hnCD16-IL15RF) | N/A | rituximab | Human BL | Preclinical | 2019 | [92] |
| PB | irradiated k562-mbIL15-41BBL | No | No | Obinutuzumab | Human BL | Preclinical | 2015 | [93] |
| PB | No | No | No | CD19/CD16 BiKE CD19/CD22/CD16 TriKE | Human BL | Preclinical | 2012 | [94•] |
| PB | No | No | No | 161519 TriKE | Human BL | Preclinical | 2012 | [95] |
| PB | No | No | No | CD30/CD16A (AFM13) tandem diabody | Human HL | Preclinical | 2014 | [96] |
| PB | No | No | No | rituximab | Human BL FL | Preclinical | 2016 | [97] |
| PB | No | No | No | N-820 | Human BL | Preclinical | 2016 | [98] |
| PB | irradiated k562-mbIL21-41BBL | No | No | N-820 | rituximab sensitive and resistant human BL | Preclinical | 2020 | [99] |
CB cord blood; PB peripheral blood; hESC human embryonic stem cell; SCF stem cell factor; Flt3L Flt3 ligand; iPSC induced pluripotent stem cell; ML memory-like; NAM nicotinamide; iC9 inducible caspase-9; CAR chimeric antigen receptor; hnCD16 high-affinity, non-cleavable CD16; BL Burkitt lymphoma; FL follicular lymphoma; mRNA messenger ribonucleic acid; Ref. references